Literature DB >> 24703906

A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.

Hiromi Yamazaki1, Mikiko Suzuki2, Akihito Otsuki1, Ritsuko Shimizu3, Emery H Bresnick4, James Douglas Engel5, Masayuki Yamamoto6.   

Abstract

Chromosomal inversion between 3q21 and 3q26 results in high-risk acute myeloid leukemia (AML). In this study, we identified a mechanism whereby a GATA2 distal hematopoietic enhancer (G2DHE or -77-kb enhancer) is brought into close proximity to the EVI1 gene in inv(3)(q21;q26) inversions, leading to leukemogenesis. We examined the contribution of G2DHE to leukemogenesis by creating a bacterial artificial chromosome (BAC) transgenic model that recapitulates the inv(3)(q21;q26) allele. Transgenic mice harboring a linked BAC developed leukemia accompanied by EVI1 overexpression-neoplasia that was not detected in mice bearing the same transgene but that was missing the GATA2 enhancer. These results establish the mechanistic basis underlying the pathogenesis of a severe form of leukemia through aberrant expression of the EVI1 proto-oncogene.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24703906      PMCID: PMC4012341          DOI: 10.1016/j.ccr.2014.02.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  58 in total

1.  Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells.

Authors:  M Shimabe; S Goyama; N Watanabe-Okochi; A Yoshimi; M Ichikawa; Y Imai; M Kurokawa
Journal:  Oncogene       Date:  2009-12-10       Impact factor: 9.867

Review 2.  GATA switches as developmental drivers.

Authors:  Emery H Bresnick; Hsiang-Ying Lee; Tohru Fujiwara; Kirby D Johnson; Sunduz Keles
Journal:  J Biol Chem       Date:  2010-07-29       Impact factor: 5.157

3.  Acetylation of lysine 564 adjacent to the C-terminal binding protein-binding motif in EVI1 is crucial for transcriptional activation of GATA2.

Authors:  Akiko Shimahara; Norio Yamakawa; Ichiro Nishikata; Kazuhiro Morishita
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

Review 4.  GATA factor switching during erythroid differentiation.

Authors:  Hiroshi Kaneko; Ritsuko Shimizu; Masayuki Yamamoto
Journal:  Curr Opin Hematol       Date:  2010-05       Impact factor: 3.284

5.  EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization.

Authors:  S Goyama; E Nitta; T Yoshino; S Kako; N Watanabe-Okochi; M Shimabe; Y Imai; K Takahashi; M Kurokawa
Journal:  Leukemia       Date:  2009-09-24       Impact factor: 11.528

6.  A single cis element maintains repression of the key developmental regulator Gata2.

Authors:  Jonathan W Snow; Jennifer J Trowbridge; Tohru Fujiwara; Nikla E Emambokus; Jeffrey A Grass; Stuart H Orkin; Emery H Bresnick
Journal:  PLoS Genet       Date:  2010-09-09       Impact factor: 5.917

7.  Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease.

Authors:  Stefan Stein; Marion G Ott; Stephan Schultze-Strasser; Anna Jauch; Barbara Burwinkel; Andrea Kinner; Manfred Schmidt; Alwin Krämer; Joachim Schwäble; Hanno Glimm; Ulrike Koehl; Carolin Preiss; Claudia Ball; Hans Martin; Gudrun Göhring; Kerstin Schwarzwaelder; Wolf-Karsten Hofmann; Kadin Karakaya; Sandrine Tchatchou; Rongxi Yang; Petra Reinecke; Klaus Kühlcke; Brigitte Schlegelberger; Adrian J Thrasher; Dieter Hoelzer; Reinhard Seger; Christof von Kalle; Manuel Grez
Journal:  Nat Med       Date:  2010-01-24       Impact factor: 53.440

8.  Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells.

Authors:  Susumu Goyama; Go Yamamoto; Munetake Shimabe; Tomohiko Sato; Motoshi Ichikawa; Seishi Ogawa; Shigeru Chiba; Mineo Kurokawa
Journal:  Cell Stem Cell       Date:  2008-08-07       Impact factor: 24.633

9.  GATA2-dependent and region-specific regulation of Gata2 transcription in the mouse midbrain.

Authors:  Daisuke Nozawa; Norio Suzuki; Maki Kobayashi-Osaki; Xiaoqing Pan; James Douglas Engel; Masayuki Yamamoto
Journal:  Genes Cells       Date:  2009-04-13       Impact factor: 1.891

10.  Myeloid transforming protein Evi1 interacts with methyl-CpG binding domain protein 3 and inhibits in vitro histone deacetylation by Mbd3/Mi-2/NuRD.

Authors:  Dominik Spensberger; Michiel Vermeulen; Xavier Le Guezennec; Renee Beekman; Antoinette van Hoven; Eric Bindels; Henk Stunnenberg; Ruud Delwel
Journal:  Biochemistry       Date:  2008-05-24       Impact factor: 3.162

View more
  84 in total

Review 1.  GATA2 deficiency.

Authors:  Amy P Hsu; Lisa J McReynolds; Steven M Holland
Journal:  Curr Opin Allergy Clin Immunol       Date:  2015-02

2.  The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features.

Authors:  Marion Eveillard; Jacques Delaunay; Steven Richebourg; Laurence Lodé; Richard Garand; Soraya Wuillème; François Duhoux; Hélène Antoine-Poirel; Catherine Godon; Marie C Béné
Journal:  Haematologica       Date:  2015-03       Impact factor: 9.941

Review 3.  Blood disease-causing and -suppressing transcriptional enhancers: general principles and GATA2 mechanisms.

Authors:  Emery H Bresnick; Kirby D Johnson
Journal:  Blood Adv       Date:  2019-07-09

Review 4.  The GATA factor revolution in hematology.

Authors:  Koichi R Katsumura; Emery H Bresnick
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

5.  Enhancer-gene rewiring in the pathogenesis of Quebec platelet disorder.

Authors:  Minggao Liang; Asim Soomro; Subia Tasneem; Luis E Abatti; Azad Alizada; Xuefei Yuan; Liis Uusküla-Reimand; Lina Antounians; Sana Akhtar Alvi; Andrew D Paterson; Georges-Étienne Rivard; Ian C Scott; Jennifer A Mitchell; Catherine P M Hayward; Michael D Wilson
Journal:  Blood       Date:  2020-12-03       Impact factor: 22.113

6.  Derepression of the DNA Methylation Machinery of the Gata1 Gene Triggers the Differentiation Cue for Erythropoiesis.

Authors:  Lei Yu; Jun Takai; Akihito Otsuki; Fumiki Katsuoka; Mikiko Suzuki; Saori Katayama; Masahiro Nezu; James Douglas Engel; Takashi Moriguchi; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2017-03-31       Impact factor: 4.272

7.  Molecular basis of crosstalk between oncogenic Ras and the master regulator of hematopoiesis GATA-2.

Authors:  Koichi R Katsumura; Chenxi Yang; Meghan E Boyer; Lingjun Li; Emery H Bresnick
Journal:  EMBO Rep       Date:  2014-07-23       Impact factor: 8.807

8.  Predictive value of high EVI1 expression in AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation in first CR.

Authors:  X He; Q Wang; J Cen; H Qiu; A Sun; S Chen; D Wu
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

9.  Expression Pattern and Prognostic Significance of EVI1 Gene in Adult Acute Myeloid Leukemia Patients with Normal Karyotype.

Authors:  Irena Marjanovic; Teodora Karan-Djurasevic; Tatjana Kostic; Marijana Virijevic; Nada Suvajdzic-Vukovic; Sonja Pavlovic; Natasa Tosic
Journal:  Indian J Hematol Blood Transfus       Date:  2019-11-04       Impact factor: 0.900

Review 10.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.